scholarly journals CHANGES IN BRONCHIAL ASTHMA CONTROL AND INFLAMMATION BIOMARKERS DURING THE ALLERGEN-SPECIFIC IMMUNOTHERAPY AND ACCOMPANYINGTREATMENT

2011 ◽  
Vol 8 (2) ◽  
pp. 44-50
Author(s):  
T I Eliseeva ◽  
Yu S Kul'gina ◽  
I I Balabolkin ◽  
T I Eliseeva ◽  
U S Kulgina ◽  
...  
Keyword(s):  
Asthma Control ◽  
Bronchial Asthma ◽  
Specific Immunotherapy ◽  
Inhaled Corticosteroids ◽  
Total Concentration ◽  
Allergic Inflammation ◽  
Exhaled Breath ◽  
Allergen Specific Immunotherapy ◽  
Exhaled Air ◽  
Ic Treatment

Background. The work is devoted to the studying of the correspondence between the symptoms dynamics and the concentrations of the nitrogen oxide (NO) methabolites in the exhaled breath air condensate in patients with bronchial asthma (BA) during allergenospecific immunotherapy (ASIT) and accompanying treatment. Methods. The symptoms of BA were estimated using the Asthma Control Questionaire (ACQ). The inflammation biomarkers level (NO methabolites in the exhaled air condensate) was measured by the spectrofluorometric method of Griess. Results. During ASIT and accompanying treatment (cetirizine or levocetirizine with basis BA therapy corresponding to the observed BA severity with allergens eliminated), the symptoms reduction (decrease in the total ACQ scores) was observed along with decrease of the total concentration of NO metabolites in blood. This was observed both for the steroid- naive patients and for the patients taking the inhaled corticosteroids (IC) treatment. Conclusion: In patients with mild BA, combination of ASIT and non-steroid accompanying therapy on the basis of cetirizine or levocetirizine results in the improvement of the BA control and reduction of the allergic inflammation in airways comaparable to the analogous processes in patients with moderate BA taking the analogous therapy but with IC included.

Clinical and genetic associations of NO-synthase and arginase gene polymorphisms and gene-gene interactions in children with bronchial asthma

2020 ◽  
Vol 15 (5) ◽  
pp. 7-17
Author(s):  
B.Ts. Batozhargalova ◽  
◽  
Yu.L. Mizernitsky ◽  
S.E. Dyakova ◽  
N.V. Petrova ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Gene Polymorphisms ◽  
Tandem Repeats ◽  
Inhaled Corticosteroids ◽  
Disease Onset ◽  
Clinical Manifestations ◽  
N Gene ◽  
Gene Interactions ◽  
Exhaled Air ◽  
S Allele

Objective. To analyze the association between NOS1, NOS2, NOS3, ARG1, and ARG2 gene polymorphisms and clinical, laboratory, and functional characteristics of bronchial asthma (BA) in children by evaluating gene-gene interactions. Patients and methods. We have evaluated the associations between the NOSs and ARG genes and gene-gene interactions in 107 children with BA. We performed comparative genetic analysis of associations between polymorphic variants of candidate genes in 107 BA patients and clinical manifestations of the disease, laboratory, and functional parameters. Results. We have found an association between the short (S) allele and SS genotype of the NOS1 (AAT)n gene and early disease onset (<5 years), severe BA, and antiinflammatory targeted therapy (with omalizumab and combination inhaled corticosteroids with long-acting β2-agonists). We have also revealed an association between the short (S) allele and SS genotype of the NOS1 (AAT)n gene, as well as long (L) alleles and LL genotypes of the NOS2A (CCTTT)n gene in BA patients and elevated FeNO levels in the exhaled air. The following association have also been identified: between alleles and genotypes containing long (L) tandem repeats in the NOS2A (CCTTT)n gene and reduced FEV1; between AG genotype of the ARG2 gene (rs3742879), alleles and genotypes containing long tandem repeats (L) of the NOS2А (CCTTT)n gene and reduced FEV1/ FVC; between alleles and genotypes containing long tandem repeats (L), combinations of genotypes SL+LL of the NOS2А (CCTTT)n and impaired patency at the level of the middle bronchi FEF50; between allele G, heterozygous genotype AG of the ARG2 (rs3742879) gene with impaired patency at the level of peripheral bronchi FEF75. Conclusion. Our analysis of gene-gene interactions has demonstrated phenotypic characteristics of BA: early BA onset, severe BA, decreased FEV1 and FEF50, increased NO concentration in exhaled air, and presence of fungal and epidermal sensitization. Key words: children, bronchial asthma, NOS and ARG gene polymorphisms, gene-gene interactions

Levels of natural antibodies to endotoxin in bronchial asthma patients undergoing allergen specific immunotherapy (SIT)

2003 ◽  
Vol 111 (2) ◽  
pp. S71 ◽  
Author(s):  
V.A. Beloglazov ◽  
A.I. Gordienko ◽  
A.A. Bakova ◽  
L.N. Znamenskaya ◽  
A.V. Rozovenko ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Specific Immunotherapy ◽  
Natural Antibodies ◽  
Allergen Specific Immunotherapy ◽  
Asthma Patients

scholarly journals Breathomics in Asthmatic Children Treated with Inhaled Corticosteroids

Metabolites ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 390
Author(s):  
Valentina Agnese Ferraro ◽  
Silvia Carraro ◽  
Paola Pirillo ◽  
Antonina Gucciardi ◽  
Gabriele Poloniato ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Healthy Children ◽  
Asthmatic Children ◽  
Inhaled Steroids ◽  
Steroid Profile ◽  
Indirect Analysis

Background: “breathomics” enables indirect analysis of metabolic patterns underlying a respiratory disease. In this study, we analyze exhaled breath condensate (EBC) in asthmatic children before (T0) and after (T1) a three-week course of inhaled beclomethasone dipropionate (BDP). Methods: we recruited steroid-naive asthmatic children for whom inhaled steroids were indicated and healthy children, evaluating asthma control, spirometry and EBC (in asthmatics at T0 and T1). A liquid-chromatography–mass-spectrometry untargeted analysis was applied to EBC and a mass spectrometry-based target analysis to urine samples. Results: metabolomic analysis discriminated asthmatic (n = 26) from healthy children (n = 16) at T0 and T1, discovering 108 and 65 features relevant for the discrimination, respectively. Searching metabolomics databases, seven putative biomarkers with a plausible role in asthma biochemical–metabolic processes were found. After BDP treatment, asthmatic children, in the face of an improved asthma control (p < 0.001) and lung function (p = 0.01), showed neither changes in EBC metabolomic profile nor in urinary endogenous steroid profile. Conclusions: “breathomics” can discriminate asthmatic from healthy children, with prostaglandin, fatty acid and glycerophospholipid as putative markers. The three-week course of BDP—in spite of a significant clinical improvement—was not associated with changes in EBC metabolic arrangement and urinary steroid profile.

scholarly journals CLINICAL EFFICACY OF SUBLINGUAL ALLERGEN IMMUNOTHERAPY WITH ANTIPOLLIN MIXED WEEDS IN ADULTS

2016 ◽  
Vol 13 (4-5) ◽  
pp. 68-71
Author(s):  
E F Glushkova ◽  
O I Sidorovich
Keyword(s):  
Visual Analogue Scale ◽  
Asthma Control ◽  
Clinical Efficacy ◽  
Analogue Scale ◽  
Allergen Immunotherapy ◽  
Specific Immunotherapy ◽  
Nasal Congestion ◽  
Respiratory Allergy ◽  
Asthma Control Questionnaire ◽  
Allergen Specific Immunotherapy

Background. To evaluate the effectiveness of one course of sublingual allergen-specific immunotherapy (sASIT) in adults with allergy to wormwood and goose-foot pollen. Materials and methods. 28 adults aged between 20 and 53 years old with various forms of respiratory allergy were included in the study. All of them received sASIT with Antipollin Mixed weeds. The effectiveness of treatment was assessed using a visual analogue scale of rhinoconjunctivitis symptoms and Asthma Control Questionnaire. Results. As a result of sASIT a 61,6% of rhinorrhea, a 61,6% of nasal congestion , a 71,43% of nasal itching, and 82% of eyes itching reduction was shown as well as asthma control was achieved in 83,3% of patients.

scholarly journals DURATION OF CLINICAL EFFECT OF LOW-DOSE SUBLINGUAL-PERORAL ALLERGEN-SPECIFIC IMMUNOTHERAPY OF BRONCHIAL ASTHMA

2021 ◽  
Vol 19 (2) ◽  
pp. 202-206
Author(s):  
A. V. Sidarenka ◽  
◽  
L. R. Vykhristsenka ◽  
Keyword(s):  
Bronchial Asthma ◽  
Adverse Reactions ◽  
Low Dose ◽  
Specific Immunotherapy ◽  
Adherence To Treatment ◽  
Allergen Specific Immunotherapy ◽  
Negative Effect ◽  
Full Adherence ◽  
Observation Period

Background. Allergen-specific immunotherapy (ASIT) affects the immune response and the clinical course of bronchial asthma (BA). Objective. To evaluate the clinical efficacy of sublingual-oral low-dose ASIT in asthma based on the results of 5-year follow-up. Material and Methods. ASIT was carried out with a mixture of household allergens in 51 patients aged 18-60 years old. The patient's opinion, the number and severity of BA exacerbations, the duration of post-immunotherapeutic remission and the factors influencing it, adherence to treatment, and the safety of treatment were taken into account. Results. The effectiveness of ASIT according to the patient’s opinion: 45.1% - excellent, 49% - good result. In allergic asthma, remission after ASIT was significantly higher than in mixed asthma. Full adherence to treatment (3 courses of ASIT) - in 76.5% (39/51) of patients. There were no adverse reactions during the entire observation period. The mixed BA phenotype, contact with the allergen in everyday life, and smoking had a negative effect. Positive - high compliance to therapy. Conclusions. Sublingual-oral ASIT is an effective and safe method of treating allergic and mixed asthma. The duration of post-immunotherapeutic remission of BA for 3 years was observed after 3 courses of ASIT.

Sign in / Sign up

Export Citation Format

Share Document